Introduction
The inhibitors of differentiation or DNA-binding proteins (Id1-4) are dominant inhibitors of helix-loop-helix (HLH) transcription factors. They inhibit the activities of several classes of basic helix-loop-helix (bHLH) transcription factors [1] , retinoblastoma (Rb) ''pocket'' proteins [2] , Ets domain proteins [3] , and Pax homeodomain-containing proteins [4] . Their interference with the key regulatory bHLH proteins is established as an important interaction for cell cycle regulation [1] . In most cases, Id1 and Id3 interact exclusively with class A bHLH proteins. Within class A members, they preferentially dimerize with E-proteins: E12/E47, E2-2, and HEB [5] . While E-proteins activate transcription by binding to promoter E-boxes, Id proteins lacking basic DNA-binding domain form DNAbinding incompetent heterodimers with E-proteins. This leads to the transcriptional repression of different cell cycle regulators, which implies important roles of Ids for cell fate decision of growth and differentiation [6, 7] .
Expression of Id proteins is typically high in actively proliferating cells and is downregulated as a prerequisite for exit from the cell cycle and terminal differentiation [8, 9] . Id proteins promote cell proliferation by regulating the expression of genes or activities of proteins involved in cell cycle such as the cyclin-dependent kinase inhibitors CDKN1A [10] , CDKN1B [11] , CDKN2A [12] , and the retinoblastoma tumor suppressor protein pRb [2] . Upregulated Id activity is tumorigenic [11] . Overexpression of Id proteins, especially Id1, is frequently found in several human malignancies including breast cancer, and seems to correlate with unfavorable clinical prognosis [13] [14] [15] [16] . The low postnatal expression of Ids and their roles in tumorigenesis, tumor invasiveness, metastasis, and neoangiogenesis mark them as attractive targets for anticancer therapy [11] . Inhibition studies have shown that the functions of Id proteins can be downregulated through Id-specific antisense oligonucleotides or small interference RNAs, and their downregulation can cause growth arrest and induction of apoptosis in various tumor cells [11] . Targeting Id1 expression in breast cancer cells reduces breast cancer metastasis in animal models [17, 18] . Mice lacking Id1/Id3 genes are resistant to xenotransplanted tumor grafts and show defects in tumor neoangiogenesis [19] . Different breast tumors failed to grow and/or metastasize in Id1
?/-Id3 -/-mice [20] . So far the functions of Id1 and Id3 have been inhibited only through interference at DNA or RNA levels. Based on these observations, this study was designed to identify peptide aptamers having the potential to block the intracellular functions of Id proteins. Peptide aptamers represent short peptides of random sequences. Based on their in vivo binding affinity to their target protein, they can be selected from randomized combinatorial expression libraries using yeast and mammalian two-hybrid systems [21] [22] [23] . They bear some analogies with the monoclonal antibodies, with the advantage that they are isolated with their coding sequences and their small size would allow to elucidate their structure. Peptides delivered into cells by protein transduction domains (PTDs) can selectively inhibit the activities of their target proteins in a dose-and time-dependent fashion [24, 25] . Thus, they represent powerful alternative tools to the approaches of the antibody-based inhibition model or siRNA-based gene-silencing method.
Here, we present a novel peptide aptamer, Id1/3-PA7, specifically interacting with Id1 and Id3. It inhibited the heterodimerization of E47 with Id1 or Id3, enhanced E-box promoter activity, and elevated the expression of tumor suppressors CDKN1A and CDKN1B in a dose-dependent manner. It induced additionally PARP cleavage. Id1/3-PA7 exacerbated both cell cycle arrest and apoptosis in breast cancer cells.
Materials and methods
Cell lines and cell culture MCF7 and MDA-MB-231 cell lines were purchased in October 2007 from the American Type Culture Collection (ATCC, Manassas, USA). HeLa cell line was purchased in November 2007 from German Collection of Microorganisms, and Cell Cultures (DSMZ, Braunschweig, Niedersachsen, Germany). MCF7 and HeLa cell lines were grown in EMEM (ATCC), and MDA-MB-231 cell lines in Leibovitz's L-15 Medium (ATCC). Growth media EMEM and Leibovitz's L-15 were supplemented with 10% fetal bovine serum (ATCC), penicillin (50 U/ml), streptomycin (50 mg/ml), and 2 mM glutamine (Sigma, Deisenhofen, Bayern, Germany). For growing of MCF7 cell lines, 5 mg/ml insulin (Sigma) was added, and MDA-MB-231 cell lines were grown in 100% atmospheric air without CO 2 . All cell lines were tested and authenticated in February 2008 by the Genetic Core Facility at German Cancer Research Center using the method Multiplex cell Contamination Test (McCT) (http://www.dkfz.de/gpcf/ contamination-control.html).
Transfections
For luciferase assays HeLa and MCF7 cells were transiently transfected using calcium phosphate method [26] . For the analysis of PARP cleavage or CDKN1A and CDKN1B expressions, MCF7 and MDA-MB-231 cells were transfected using the FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, USA). Cells were selected with 1 mg/ml G418 (Sigma, Deisenhofen, Bayern, Germany). Transfections were monitored by immunoblot detection of the expressed proteins.
Yeast two-hybrid screening of peptide aptamers
The screening was done in the yeast strain MaV203 (MATa, leu2-3,112, trp1-901, his3D200, ade2-101, gal4D, gal80D, SPAL10::URA3, GAL1::lacZ, HIS3 UAS GAL1 :: HIS3@LYS2, can1 R , cyh2 R ). As baits, full length of human Id1, Id2, and Id3 were fused to the GAL4-DBD into the pPC97 vector (pPC97-Id1, pPC97-Id2, or pPC97-Id3). Screenings were done with randomized constrained peptide aptamer library (pADtrx-aptamers), and selection procedures were performed as described previously [21] . Bacterial expression and purification of PTD-fused peptide aptamers A PTD, truncated VP22 ORF [24, 25] , was used for the intracellular delivery of the peptide aptamer. PTD was fused to the C-terminus of the peptide aptamers or TrxA, which were inserted into the vectors, pCR T7/VP22-1-TOPO and pCR T7/VP22/NES-2-TOPO (Invitrogene, Carlsbad, USA). Bacterial expression of the peptide aptamer was induced with isopropyl-1-thio-b-D-galactopyranoside (1 mM) for 5 h at room temperature. The peptide aptamers were furnished with 69 His-tag to facilitate their purification by nickel chelate chromatography. Purification of the peptide aptamer was done under native conditions using ProBond Purification System (Invitrogene, Carlsbad, USA). The purity of the peptide aptamer was investigated by gel electrophoresis and coomassie staining. The concentration was determined by BCA Protein Assay Kit (Pierce, Rockford, USA).
Immunofluorescence and immunoblotting
For immunofluorescence analysis, cells were grown on cover slips, fixed, and permeabilized in methanol for 20 min at -20°C, and then rehydrated with PBS. Before immunostaining with the indicated antibodies, cells were blocked in normal serum (1:10 in PBS containing 5% BSA). Nuclei were visualized by using Prolong Gold Antifade Reagent with DAPI (Invitrogene, Carlsbad, USA). Cells were analyzed using Carl Zeiss AxioVision 4 microscope equipped with Carl Zeiss AxioCam digital camera and software version Carl Zeiss AxioVision Rel. 4.6.3 (Carl Zeiss Vision GmbH, Jena, Thueringen, Germany).
For immunoblot experiments, cell lysates prepared in EBC buffer (50 mM Tris-HCl, 120 mM NaCl, 1% (v/v) Nonidet P40, pH 8.0) supplemented with protease and phosphatase inhibitors were separated by SDS-PAGE and electrotransferred to polyvinylidene fluoride membranes (Millipore, Temecula, USA). In order to detect antigen/ antibody complexes membranes were incubated with appropriate horseradish peroxidase-labeled secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, USA) and developed for enhanced chemiluminescence using the ECL WB Detection Kit (Millipore, Temecula, USA).
Primary antibodies used were anti-Id1 (C-20), anti-Id3 (C-20) (Santa Cruz Biotechnology, Santa Cruz, USA), antia tubulin, anti-Trx (Sigma, Deisenhofen, Bayern, Germany), anti-CDKN1A, anti-CDKN1B (Millipore, Temecula, USA), and anti-PARP (BD Biosciences, San Jose, USA). Secondary antibodies used were goat anti-mouse or goat anti-rabbit Alexa Fluor 488, 660, and 680 for immunofluorescence experiments and HRP-conjugated goat anti-rabbit and goat anti-mouse (Santa Cruz Biotechnology, Santa Cruz, USA) for immunoblotting.
Coimmunoprecipitation
MCF7 and MDA-MB-231 cells were treated with peptide aptamer Id1/3-PA7 (5 lg/10 6 cells). After 1.5 h, cells were lysed in RIPA Buffer (Pierce, Rockford, USA) containing protease and phosphatase inhibitors. Protein samples were purified by nickel chelate chromatography under native conditions using ProBond Purification System (Invitrogene, Carlsbad, USA) and analyzed by Western blotting using antibodies against Trx, Id1, and Id3.
E-box promoter-reporter assays pGL4.1-4Rtk-luc (E-box-dependent-reporter-construct), pcDNA3-E47, pCMV-Id1, and pCMV-Id3 along with pCMV-LacZ as an internal standard were used for transfection of MCF7 cells. After transfection, cells were treated by adding Id1/3-PA7 (5 lg/10 6 cells) in 4 h intervals for 48 h. Cell lysis and measurement of luciferase activity were done as described in the above experiment of mammalian two-hybrid assays.
RNA analysis
Cells were treated with different doses of Id1/3-PA7 (1-7.5 lg/10 6 cells) in 4 h intervals for 48 h. Total RNA was purified using RNeasy Plus Mini Kit (QIAGEN, Hilden, Nordrhein-Westfalen, Germany) and inspected by agarose gel electrophoresis. cDNAs were synthesized using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, USA). The mRNAs of CDKN1A, CDKN1B, and b-Actine as internal standard were measured by real time PCR with TaqMan gene expression assays (Applied Biosystems) using the LightCycler 480 Real-Time PCR System and LightCycler 480 Probes Master (Roche Applied Science, Mannheim, Baden-Wuerttemberg, Germany). Program: 15 min at 95°C activation, 40 cycles of 15 s at 95°C followed by 30 s at 55°C and 1 s at 72°C, melting 1 s at 55°C, and cooling 1 min at 40°C. For the relative quantification of the mRNA levels, three independent amplifications were performed for each probe, with triplicate samples. The relative mRNA levels were numerically presented using the comparative 2 T -DDc method.
Flow cytometry cell cycle analysis Cells were treated with Id1/3-PA7 (5 lg/10 6 cells) in 4 h intervals for 48 h. For quantitative cell cycle analysis, BD Pharmingen FITC BrdU Flow Kit (BD Biosciences, San Jose, USA) was used. Prolonged cell exposure (6 h) to BrdU allowed identification and analysis of actively cycling, as opposed to non-cycling, cell fractions. The measurement of cell incorporated BrdU (with FITC antiBrdU) and total DNA content (with 7-AAD) in cells was performed using the BD FACSCalibur Flow Cytometer (BD Biosciences, San Jose, USA).
Results

Screening of Id protein-specific peptide aptamers
Using yeast two-hybrid system, we aimed to identify peptide aptamers that would specifically bind to Id proteins. For screening of peptide aptamers, we used a yeast two-hybrid peptide aptamer expression library encoding 2 9 10 8 random peptides of 20 amino acids, which are displayed by the active-site loop of Escherichia coli thioredoxin (TrxA). Using wild type Id1 as bait construct subsequently transformed with expression vectors encoding the random peptide library in yeast strain MaV203, which contains three selectable markers (His3, Ura3, and LacZ) under the control of three different GAL4-binding promoter regions, we isolated 37 positive hits from the library. We sequenced the peptide aptamers from all the 37 clones and identified 30 clones of different peptide aptamers (Table 1) , which grew in the absence of uracil, histidine, and were blue on selection plate containing X-Gal. As Id proteins exhibit high sequence homologies within their HLH domains, have commonbinding partners and partially overlapping functions, we examined whether the isolated 30 peptide aptamers also interact with Id2 and Id3. We found that one of the peptide aptamers also interacted with Id2, and six peptide aptamers interacted with Id3 (Table 1) (Table 1) . Blast searches with all the identified peptide aptamers revealed no sequence similarities with known proteins. All Id-binding peptide aptamers did not show more than random similarity to any other.
Specific interaction of the peptide aptamers with Id proteins in human cells
In order to confirm the interaction of in yeast two-hybrid selected peptide aptamers with Id proteins in human cells, mammalian two-hybrid experiments in HeLa cells were performed. All the 30 peptide aptamers and all the four Id genes were subcloned into mammalian expression vectors pACT and pBIND as prey and bait, respectively. We used the luciferase reporter gene construct pG5luc, which is under the control of the GAL4-DBS. HeLa cells were transfected with bait, prey, and luciferase constructs along with pCMV-LacZ as an internal standard. Interactions of peptide aptamer 5 (Id1-PA5) and peptide aptamer 17 (Id1-PA17) with Id1, peptide aptamer 7 (Id1/3-PA7) with Id1 and Id3, peptide aptamer 10 (Id3-PA10) with Id3, and peptide aptamer 13 (Id1-4-PA13) with all Ids were verified (Fig. 1a) . Our goal was obtaining peptide aptamers that bind to Id proteins, but not to their binding partners. Accordingly, we tested the interaction of the five peptide aptamers with Id-binding proteins. None of the five peptide aptamers interacted with E47, MyoD, ETS1, ETS2, and S5A (Fig. 1b) .
Id1/3-PA7 induces E-box promoter activity
The mere binding ability of the peptide aptamers to Id proteins does not necessarily imply functional interference with the Ids. For the intracellular delivery, the peptide aptamers and TrxA were cloned into vectors pCR T7/VP22-1-TOPO and pCR T7/VP22/NES-2-TOPO to express them in fusion with cell-penetrating PTD [24, 25] . Although all recombinant peptide aptamers and TrxA were expressed in bacteria, only Id1/3-PA7 and TrxA were successfully purified under native conditions. Breast cancer cells MDA-MB-231 and MCF7 (cultured in 10% serum) overexpressing Id1 and Id3 were treated with Id1/3-PA7 (5 lg/10 6 cells). After a treatment for 1.5 h, the internalization of the peptide aptamer into cells and its colocalization with Id1 and Id3 were verified by His-tag co-immunoprecipitation (Fig. 2a, b) . TrxA-treated cells were used as negative control (Fig. 2c, d ). In addition, we verified its colocalization with Id1 and Id3 by co-immunofluorescence staining in MCF7 cells (Fig. 2e, f) . Id1/3-PA7 untreated MCF7 cells were used as negative control (Fig. 2g) . In order to analyze the potency of Id1/3-PA7 with respect to Id1 and Id3 inhibition and restoration of E-box promoter activity, we used the E-box-dependent reporter gene 4Rtk-luc, which contains four tandem E-boxes from the MCK enhancer upstream of the thymidine kinase basal promoter [27] . MCF7 cells were transfected with 4Rtk-luc, pcDNA3-E47, pCMV-Id1, pCMV-Id3, and pCMV-LacZ as an internal standard. After transfection, cells were treated with Id1/3-PA7 (5 lg/10 6 cells, half-life 2.5 h) in 4 h 
30 peptide aptamers (PA1-30) interacting with Id1 were screened using yeast two-hybrid system. One of the peptide aptamers (PA30) interacted also with Id2 and six of the peptide aptamers (PA6-10 and PA13) interacted with Id3. Negative control: interactions of peptide aptamers with the empty vector pPC97, and interactions Id proteins with the empty vector pADtrx intervals for 48 h. The reporter gene was upregulated in the presence of E47. E47-dependent activation was reduced in the presence of Id1 or Id3 and with the addition of Id1/3-PA7, the activation was restored again (Fig. 2h) . Treatment of cells with TrxA (5 lg/10 6 cells) had no effect on the E-box promoter activity (Fig. 2h ).
Id1/3-PA7 upregulates expression of CDKN1A and CDKN1B E-proteins activate transcription by binding to promoter E-boxes. Formation of heterodimers between Id protein and E-protein prevents E-proteins from forming DNA-binding transcriptionally active complexes. This inhibits E-box promoter-dependent transcriptional activation of the tumor suppressor genes CDKN1A and CDKN1B. We analyzed the effects of Id1/3-PA7 on expression levels of CDKN1A and CDKN1B by real time PCR and Western blotting. Breast cancer cells MCF7 and MDA-MB-231 were treated with different doses of Id1/3-PA7 (1-7.5 lg/10 6 cells) in 4 h intervals for 48 h. Transduction of Id1/3-PA7 caused dose-dependent increase in mRNA and protein levels of CDKN1A and CDKN1B compared to that in untreated or TrxA-treated cells (Fig. 3a-d) . These increased expression levels of CDKN1A and CDKN1B were counteracted by ectopically overexpressed Id1 and Id3 (Fig. 3a, b ).
Id1/3-PA7 induces cell cycle arrest and apoptosis in breast cancer cells CDKN1A and CDKN1B block cell cycle progression by inhibiting the activities of cyclin-dependent kinases [28, 29] and prevent DNA synthesis by interacting with the proliferating cell nuclear antigen [30] . Using flow cytometry, we analyzed the effects of Id1/3-PA7 on cell cycle progression and apoptosis in breast cancer cells MCF7 and MDA-MB-231. Cells were treated with Id1/3-PA7 (5 lg/10 6 cells) in 4 h intervals for 48 h. For the identification and analysis of actively cycling, as opposed to non-cycling, cell fractions, we prolonged the exposure of untreated and TrxA or Id1/3-PA7-treated cells to BrdU for 6 h. The cell cycle positions and active DNA synthetic activities of cells were determined by analyzing the correlated expression of total DNA and incorporated BrdU levels as shown by the region gates applied to the 7-AAD versus BrdU dot plot (Fig. 4a-f) . Flow cytometric analysis of untreated cells versus Id1/3-PA7-treated cells showed that the antiproliferative and apoptotic effects of Id1/3-PA7 reduced the number of actively cycling cells in S from 92.1 to 51.1% for MCF7 cells (Fig. 4g) and from 92.5 to 53.5% for MDA-MB-231 cells (Fig. 4i) . The number of apoptotic cells in sub G0/G1, in G0/G1, and in G2/M-resided cells increased from 2.1 to 15%, from 3.9 to 19%, and from 0.3 to 5.3%, respectively, for MCF7 cells (Fig. 4h) and from 0.9 to 13%, from 2.7 to 18.1%, and from 0.4 to 7.6%, respectively, for MDA-MB-231 cells (Fig. 4j ). There were no significant differences between flow cytometric results of untreated and TrxA-treated cells (Fig. 4a-j) .
Recently, it has been shown that treatments of different cancer cell lines with different anticancer drugs, which led to increased apoptosis rates and increased cleaved PARP were associated with downregulation of Id1 expression at both transcriptional and protein levels [31] . Ectopically overexpressed Id1 was able to suppress PARP cleavage in response to anticancer drugs [31] . Therefore, we analyzed the cleavage of PARP in Id1/3-PA7-treated MCF7 and MDA-MB-231 cells versus untreated or TrxA-treated cells. By Western blotting, we detected PARP cleavage in cell extracts of Id1/3-PA7-treated cells using anti-PARP antibody, which recognizes uncleaved PARP (113 kDa) and cleaved PARP (85 kDa) (Fig. 5a, b) . PARP cleavage was counteracted in Id1/3-PA7-treated cells by ectopically overexpressed Id1 and Id3 (Fig. 5c, d ).
Discussions
A similar expression pattern of Id1 and Id3 in many human breast cancers of various grades has been characterized [19] . The genetics of the Id1 and Id3 knockouts clearly indicate that partial loss of Id functions is sufficient in some settings to have a therapeutic effect. Mice lacking Id1/Id3 genes are resistant to xenotransplanted tumor grafts and show defects in tumor neoangiogenesis [19] . Different tumors, including B6RV2 and MMTV-HER2/neu breast h Id1/3-PA7 induced E47-dependent E-box promoter activity. E47 upregulated the E-box-dependent reporter gene [6] , Id1 or Id3 reduced E47-dependent activation [13, 14] and addition of Id1/3-PA7 restored E47-dependent activation [15, 16] . The control with TrxA showed no effect on the E-box promoter activity. Results are represented as mean values of three independent experiments with SD (P B 0.05) cancers, failed to grow and/or metastasize in Id1
?/-Id3 -/-mice [20] . Therefore, parallel inhibition of Id1 and Id3 could be a promising and effective treatment approach. Overlapping expression of Ids during cell cycle progression and their differences in binding specificities as well as regulation by phosphorylation underline different functions of Id proteins in cell cycle control. Upregulated Id activity is tumorigenic and contributes to hallmarks of malignancy. The low postnatal expression of the Ids, and their roles in tumorigenesis and tumor neoangiogenesis mark them as attractive targets for anticancer therapy [11] . Metastasis, where Id proteins are highly overexpressed, is the final and fatal step in the progression of cancer [13] [14] [15] [16] . Therapeutic strategies, which are currently available at this stage of cancer progression, are usually non-specific, highly toxic, and have only marginal efficacy. This is in part due to the lack of knowledge about the molecular mechanisms regulating the development of aggressive cancers. Approaches targeting Id expression, including gene therapy using antisense oligonucleotide, short interfering RNA, and nonviral or viral plasmid-based strategies, could have undesired biological outcomes, as they are not able to discriminate among functional domains of a protein, which could be involved in different biological interactions and diseaserelevant phenotypes. Therefore, peptide-based therapeutic approaches targeting specific mechanisms involved in the development of aggressive cancers are needed. Id proteins are expressed at very low levels in normal adult tissues and overexpressed in cancer cells, excluding thereby unwanted toxicities generally associated with currently available therapeutic modalities. Recently, it has been reported that a peptide-conjugated Id1 antisense oligonucleotide homed to tumor neovessels downregulates Id1 in tumor endothelial cells in vivo and inhibits primary tumor growth and metastasis of aggressive breast cancers in two different murine models [32] . More recently, it has been shown that targeting Id2 in human neuroblastoma cells using the HLH domain 13I, which is isolated from a phage display library of HLH domains, induces neuroblastoma cell differentiation that may restrain neuroblastoma cell tumorigenicity [33] . Here, we demonstrated for the very first time a specific, effective, and joint inhibition of Id1 and Id3 activities at protein level using a peptide aptamer Id1/3-PA7. The combined inhibition might be very important due to the fact that Id1 and Id3 have partial overlapping functions, are expressed in parallel, and might compensate for each other. Therefore, combined targeting of Id1 and Id3 could be a promising approach to treat tumors, which are associated with deregulated expression of Id1 and Id3. Id1/3-PA7 exerted in breast cancer cells MCF7 and MDA-MB-231 antiproliferative and apoptotic effects involving E-box promoter activation, upregulation of CDKN1A and CDKN1B, which is paralleled by the cleavage of PARP. The number of apoptotic cells in sub G0/G1 and in G0/G1 or in G2/M resided cells increased from 2.1 to 15%, from 3.9 to 19%, and from 0.3 to 5.3%, respectively, for MCF7 cells (h) and from 0.9 to 13%, from 2.7 to 18.1%, and from 0.4 to 7.6%, respectively, for MDA-MB-231 cells (j). There were no significant differences between results of untreated and TrxA-treated cells (a-j). Bars in i and j: black untreated, hatched TrxA treated, and white dotted Id1/3-PA7 treated. Results are represented as mean values of three independent experiments with SD (P B 0. 05) We propose that the use of Id1/3-PA7, for inhibition of Id1 and Id3 activities, could represent a novel strategy to treat breast cancer and possibly other cancers, as expression of Id proteins, especially Id1, has been found to be upregulated during the progression of different types of solid tumors [34, 35] . It could represent an alternative tool to the approaches of the antibody-based inhibition model or siRNA-based gene-silencing method. It could be used as drug leads to create more potent and efficacious peptide mimetics and non-peptide drugs with higher metabolic stability, bioavailability, and biological activity. 
